Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple duodenal ulcers due to IgA vasculitis.

Journal of the Canadian Association of Gastroenterology·2026
Same author

Editorial: Systemic sclerosis: immunological impacts.

Frontiers in immunology·2026
Same author

The clinical utility of autoantibodies in systemic sclerosis: a review with a focus on cohort differences and standardization.

Frontiers in immunology·2025
Same author

A case of digital papillary adenocarcinoma with human papillomavirus 42 detected.

The Journal of dermatology·2024
Same author

Perspective to precision medicine in scleroderma.

Frontiers in immunology·2024
Same author

Augmented interferon I signaling in a patient with COVID toes.

The Journal of dermatology·2021

Related Experiment Video

Updated: Jul 5, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.7K

CD19: a promising target for systemic sclerosis.

Kazuhiro Komura1

  • 1Department of Dermatology, Kanazawa Red Cross Hospital, Japanese Red Cross Society, Kanazawa, Ishikawa, Japan.

Frontiers in Immunology
|October 18, 2024
PubMed
Summary
This summary is machine-generated.

B cell-targeted therapies, like Uplizna® (inebilizumab) targeting CD19, show promise for treating systemic sclerosis (SSc). These treatments may improve outcomes for patients with this complex autoimmune disease.

Keywords:
CD19CD20fibrosissystemic sclerosistherapy

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.8K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

391

Related Experiment Videos

Last Updated: Jul 5, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.7K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.8K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

391

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmune Diseases

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease involving immune dysregulation, vascular damage, and fibrosis.
  • B cells are key players in SSc pathogenesis, producing autoantibodies and influencing T cell responses.
  • Current treatments like anti-CD20 therapies have shown benefits, but new targets are being explored.

Purpose of the Study:

  • To review the role of B cells in systemic sclerosis (SSc).
  • To evaluate the potential of CD19-targeted therapies, specifically Uplizna® (inebilizumab), in treating SSc.
  • To discuss the advantages of CD19 targeting over CD20 targeting in SSc management.

Main Methods:

  • Literature review of B cell involvement in SSc.
  • Analysis of existing data on B cell depletion therapies (rituximab, Uplizna®).
  • Discussion of ongoing clinical trials for Uplizna® in SSc.

Main Results:

  • B cells contribute significantly to SSc through autoantibodies and immune modulation.
  • CD19 is a promising B cell target, with therapies like Uplizna® showing potential.
  • Uplizna® may offer broader B cell targeting and higher efficacy in certain SSc patient subsets compared to rituximab.

Conclusions:

  • CD19-targeted therapies represent a promising advancement in SSc treatment.
  • Further research is needed to establish the long-term safety and efficacy of these novel therapies.
  • Targeting B cells offers a potential avenue for significantly improving outcomes in systemic sclerosis.